Find Clinical Trials & Studies

Visit the Research & Education Institute

A Phase 2 Study of MZE829 in Adults with APOL1 Kidney Disease

I'm Interested!

An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype

Sex: Any
Age: Adult (18 - 64)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase II
Conditions Being Studied: Apolipoprotein L1

Study Purpose

The main purpose of this study is to evaluate the safety of MZE829 (an investigational drug) in adults with chronic kidney disease and a high-risk APOL1 gene; and to study the effects of MZE829 on the amount of protein in your urine.

Who Can Participate

Inclusion Criteria: 18-65 years old; APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2; chronic kidney disease with persistent albuminuria

Principal Investigator
Andrew Lazar MD

Department/Division
Medicine (Nephrology)

UH IRB: STUDY20250161
StudyID: 2024-01613
ClinicalTrials.gov: N/A

I'm Interested!

Fill out our online form

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422